Providers push back on PhRMA report highlighting 340B program costs
The 340B Drug Pricing Program is heralded by providers and hated by big pharma, which has initiated a spate of regulatory and legal fights in an attempt to pare it down. The Trump administration instituted a 30% payment cut for 2019, but a federal court struck down the rate adjustment in May in a win for hospitals.
